Dhuwit awis perusahaan bicara.com (BCAX)

Simbol resmi perusahaan Bicara Bio (BCAX)

Bicara Therapeutics Inc. is developing sustainable biopharmaceuticals by minimizing toxic laboratory emissions. Growth potential is driven by the success of ficerafusp alfa and a high probability of acquisition. Innovative antibodies targeting squamous cell carcinoma are at the beginning of their life cycle. The size of the cash reserve demonstrates the level of liquid business protection, where 0.44 represents the current level of the metric.

Bicara Therapeutics Inc - Gunggung dana dhuwit perusahaan BCAX (periode 14.09.2024 - 21.11.2026)

Ringkesan rincian data analitis Bicara Therapeutics Inc (BCAX)

Pambiji fundamental:Bicara Corp
Produk merek Bicara Therapeutics

For Bicara Therapeutics Inc. (BCAX), the development of bifunctional antibodies requires colossal expenditures, meaning the current cash balance of 0.44 reflects the company's ability to fund its fight against cancer without emergency borrowing. This indicator measures the total liquidity reserve available to cover operating expenses, allowing investors to assess the capital burn rate and the business's horizon of financial autonomy in the absence of revenue.

Analisis perusahaan pesaing

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|PSNL: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan ERAS|Dhuwit awis perusahaan DCTH|Cadangan dhuwit perusahaan Y-mAbs Therapeutics Inc YMAB|Volume dana dhuwit perusahaan AURA|CADL (Candel Therapeutics, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan Accuray Inc ARAY|Aset likuid perusahaan SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Citius Oncology|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan